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Abstract
PRRS is a pig disease of major economic importance that causes respiratory and reproductive problems in pigs.
Over the last years it has become clear that PRRSV heterogeneity is increasing. Consequently, this has a potential
impact on diagnosis and strategies to counter this disease. The use of sequence-independent PCR techniques for
the detection and characterization of PRRSV could be useful to bypass problems associated with the heterogeneity
of this virus.
A random PCR cloning approach was tested for the characterization of PRRSV strain 07V063 of unknown genetic
background that circulated on a Belgian farm. By using this approach, 7305 bp of sequence data were obtained,
distributed randomly across the genome. Using RT-PCR with strain-specific primers, the full length sequence (15014
nt) was obtained. Phylogenetic relationships using ORF5 and ORF1a (NSP2) sequences showed that 07V063 was
classified in type 1 subtype 1 and that 07V063 was genetically different from prototype Lelystad Virus (LV). 07V063
showed 87-93% aa identity with LV ORFs coding for structural proteins. Most variation (compared to LV) was
noticed in Nsp2 (81% identity) with a deletion of 28 aa. This deletion was different from other known deletions in
this ORF. In conclusion, it is shown that this random PCR cloning approach can be used for the characterization of
new PRRSV strains of unknown genetic background.
Findings
P o r c i n er e p r o d u c t i v ea n dr e s p i r a t o r ys y n d r o m e( P R R S )
is an economically important viral pig disease in swine
producing countries worldwide. The virus can cause
reproductive disorders and can give rise to respiratory
problems in pigs of all ages [1]. Prevention of the dis-
ease is based on a combination of management and vac-
cination. Evidence is accumulating that PRRSV
heterogeneity is affecting the vaccination efficiency. It is
suggested that vaccines are only efficacious when the
vaccine virus and the challenge virus share a sufficiently
high homology [2-6]. PRRSV heterogeneity was origin-
ally considered mainly to occur between European (gen-
otype 1) and American type (genotype 2) PRRSV, but
current understanding shows a more complex situation
with considerable genetic variability within genotypes
[7-9]. Since such variability may affect the efficacy of
vaccination programs and pose an obstacle for PRRSV
prevention and control, knowledge on the PRRSV
strains circulating on a farm may be essential for choos-
ing an appropriate vaccine [10].
PRRSV diagnosis is mainly based on detection of
PRRSV antibodies, Reverse Transcriptase (RT) PCR or
virus isolation. Detection of antibodies by ELISA or
IPMA is not sufficient to establish the level of PRRSV
heterogeneity [11]. RT-PCR allows rapid detection and
genotyping of PRRSV, but the high degree of sequence
variation observed for PRRSV can influence results
obtained by (real-time) RT-PCR and primers and/or
probes should be carefully designed based on conserved
regions [8,12]. The development of sequence-indepen-
dent PCR techniques could be useful for the diagnosis
and genotyping of unknown PRRSV isolates and for
assessment of the PRRSV heterogeneity of field isolates.
Several methods have been developed for the identifica-
tion of viruses without prior sequence knowledge [13].
For instance, whole genome amplification and random
PCR are relatively simple. In both these methods, viral
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treated with DNAse and RNAse to remove contaminat-
ing nucleic acids. RNA and/or DNA from the viral par-
ticles is extracted and RNA is reverse transcribed to
cDNA using a primer with a random 3’end. Subse-
quently, cDNA or viral DNA is amplified using a shorter
primer (without the 3’ random end). This results in
DNA fragments of varying size (e.g. 0.5 - 2 Kb) and
these fragments can be cloned and sequenced. For
instance Allander et al. [14] used random PCR on
human respiratory tract samples which allowed identifi-
cation of several unknown viruses.
The aim of this study was to test a random PCR clon-
ing technique [14] for the detection and genotyping of a
PRRSV strain of unknown genetic background.
Random PCR cloning for the identification of PRRSV
07V063
PRRSV 07V063 was isolated from an aborted foetus from
a Belgian farm, by inoculation of porcine alveolar macro-
phages. On this farm, vaccination with Porcilis™ was in
place. PRRS diagnosis was confirmed upon detection of
cytopathic effect (CPE), and detection of PRRSV antigens
by IPMA staining with the nucleocapsid specific mAb
P3/27 [15]. The use of a random PCR approach abrogates
the need for a priori sequence information and in combi-
nation with small scale shotgun sequencing, this can
result in viral sequences. Virus 07V063 was grown on
MARC-145 cells and concentrated as described [16] and
the viral pellet was treated with DNAseI and RNAse.
RNA was extracted using commercial kits and used in
reverse transcription and random amplification using the
tagged random hexanucleotide 5’-GCCGGAGCTCTG-
CAGATATCNNNNNN-3’ for both first- and second
strand cDNA synthesis and subsequent amplification of
the cDNA with primer 5’-GCCGGAGCTCTGCAGA-
TATC-3’ [14]. Random PCR fragments ranging between
500 and 1200 bp were cloned in pCR-Blunt II-TOPO
(Invitrogen). Twenty nine clones were sequenced as
described [17]. Twenty three clones (80% of the clones)
contained PRRS sequences (Table 1). The six other
clones showed no match when performing BlastN http://
www.ncbi.nlm.nih.gov. The 07V063 sequences were ran-
domly distributed across the PRRSV genome. Several
clones were overlapping and six contigs (with sizes
between 622 and 2072 bp) were obtained (Figure 1).
Thus, without prior knowledge of the sequence it was
possible to obtain 7305 bp sequence data using a random
PCR cloning approach, hereby confirming PRRS identity.
Full length sequence of 07V063 and comparison with
prototype LV
To allow a more detailed evaluation of the PRRSV iso-
late 07V063, the full length genome sequence was
obtained using primers that were based on the 07V063
sequences from the random PCR cloning approach
(Table 2). Overlapping amplicons (spanning the com-
plete genome) were obtained using RT-PCR. Both
strands of these fragments were directly sequenced. For
the amplification of the 3’end, oligodT was used in com-
bination with ORF7fw. A 5’ end primer (5’endfw) was
designed based on the alignment of genotype 1 strains
LV (M96262), EuroPRRS (AY366525), SD01-08
(DQ489311), KNU-07 (FJ349261) and HKEU16
(EU076704). This primer was used in combination with
primer Lavgsprev to amplify the 5’end. A full length
sequence of 15014 nt was obtained. This sequence was
deposited in Genbank (Accession GU737264).
The 5’ end and 3’end of 07V063 was 221 nt and 114
nt, respectively. The size of the 5’end of 07V063 is iden-
tical with the 5’end of LV with 92.3% identity and 17 nt
Table 1 Overview of the sequences from 07V063
obtained by random PCR cloning
Clone Size (nt) Position % nt identity
49 671 774-1444 81
73 198 1692-1889 89
104 826 1808-2633 89
20 798 2616-3413 86
105 375 3069-3443 88
88 429 3420-3847 93
33 332 3957-4288 91
92 316 6198-6512 93
61 713 6367-7079 93
103 312 6768-7079 94
35 364 6500-6863 93
12 247 8132-8378 89
51 627 8931-9557 86
80 358 9200-9557 87
82 622 11225-11846 87
11 258 11225-11482 86
81 601 11928-12528 92
70 189 12336-12524 94
40 277 12364-12640 90
78 395 12991-13385 90
57 935 13195-14129 91
The position of the sequences is indicated relative to LV. % nt identity is with
LV.
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Figure 1 PRRSV genome and position of the contigs.T h e
sequences obtained in the random PCR cloning approach were
assembled in six contigs (with sizes between 622 and 2072 bp)
dispersed over the genome. The contigs are shown with a line.
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ulatory sequence (UUAACC) and CACCC stretches
(involved in binding of host cell transcription factors)
are conserved in 07V063 [18]. Table 3 gives an overview
of all ORFs in the 07V063 genome and comparison with
ORFs from prototype LV. Most variation with LV was
Table 2 Oligonucleotide primers used in RT-PCR
amplification and nucleotide sequencing of 07V063
Primer Sequence Position
5’endFW atgatgtgtagggtattccccc 1-22
Orf1univFW ccctttaaccatgtctggc 111-130
Orf1-1fw catcc gggtg ctgctgg ctt 336-355
Orf1-2fw ggag ccaccc acgtgtt gac 681-701
Lav49fw aatcaatggtattcgtgctg 1072-1091
Orf1-3-fw tcaat gcctacaa ctgcccg 1631-1650
Orf1-4-fw cttgta taaa ttgct attgg 1988-2007
Orf1-5-fw acaa cagg cctc gtaa ggg 2472-2490
Lav73fw aaaacttggcgctgcacgtc 3102-3121
Orf1-6fw ggtcc atta gcca gcgcct 3451-3469
Orf1-7fw cttgag cagcg ccaa cattg 3686-3705
Lav33fw ggtgttggcacggcgagag 4129-4147
Orf1-8fw catgg ctgtt gccca agtgt 4538-4557
Orf1-9fw ttgt gctt acgcc tggccca 4859-4878
Orf1-10fw ggcgac tcct ataat cgtat 5364-5383
Orf1-11fw ccaa gcac ttcg cagg tccg 5701-5720
Orf1-12fw ggctt ggctg ccgaaa tcgg 6096-6115
Orf1-13fw aatgaa gggag tctt gtcta 6566-6586
Lav92fw gtgtatccctcggctaccac 6891-6911
Orf1-14fw catta gtcaa cttcaa ggtt 7280-7299
Orf1-15fw gga ccc tga gcgg catgaa 7765-7783
Lav12fw ccaagaactccatggcaggt 8172-8191
Orf1-16fw ggaaaaacaaattcaaggag 8442-8461
Orf1-17fw tccag cccatg ctggt ata 8817-8835
Lav51fw gtgtttgtttcactcacact 9316-9335
Amp6fwint catcagaccatgtttgacat 9764-9783
Orf1-18fw aaggc caggaa cacca gggt 10136-10155
Orf1-19fw cccagta tttgca ccttt gc 10633-10652
Orf1-20fw cggccgta cttgc aaccag 11132-11150
Orf2afw gts aca cck tat gatta cg 11387-11406
LavORF2aseqfw gtgttcgacaacgcccacacgc 11577-11598
Orf3fw agcc taca gta caa ca ccac 12234-12253
LavORF3seq1fw agcgttgagctcatcttccc 12261-12280
Orf4fw cgg ccc ait tcc atccigag 12672-12691
Orf5Pesfw tga tca cat tcg gtt gct 13320-13337
Orf6fw tacc aa ctt tc ttc tggac 13838-13856
Orf7fw tgg cccc tgccc aic acg 14328-14345
Orf1-1-rev gtcaa cacgt gggtgg ctcc 701-681
Lavgsprev cgacttgacattctagtcca 900-881
Orf1-2-rev agat gcca aacgg acgaa cc 1304-1285
Orf1-3-rev gcag cctt cgga gcag acgc 1796-1777
ORF1-4-rev cggtg aaca cgag acacc tg 2252-2233
Orf1-5-rev gctg atgt tgtc ggatt ctg 2615-2596
Orf1-6-rev ctggg aaca ggagg cgg tgt 3202-3182
Orf1-7-rev gggttgg atg gagtc gagaa 3730-3711
Lav33rev ccccaacacttgtgacaacg 3982-3963
Orf1-8rev gt ccgag tccac tacaatc 4403-4385
Orf1-9rev agag ttgt gccac tgct gaaa 4755-4735
Amp3intrev2 cagagaaggccggttattcct 5023-5003
Amp3intrev gattccaatgagatcacca 5609-5591
Orf1-10rev gctc ggac taaaa cagc tgg 5959-5940
Table 3 Comparison of proteins from 07V63 and
prototype LV
ORF Protein Size 07V63 Size LV % identity % similarity
1a Nsp1 385 385 85 91
Nsp2 833 861 81 85
Nsp3 447 447 93 96
Nsp4 203 203 92 96
Nsp5 170 170 96 97
Nsp6 16 16 100 100
Nsp7 269 269 96 97
Nsp8 45 45 100 100
1b Nsp9 645 645 96 98
Nsp10 442 442 94 97
Nsp11 224 224 95 97
Nsp12 152 152 93 96
2a GP2 249 249 93 94
2b E 70 70 95 97
3 GP3 265 265 89 92
4 GP4 183 183 87 93
5 GP5 200 201 91 94
6 M 173 173 93 94
7 N 128 128 91 98
Table 2 Oligonucleotide primers used in RT-PCR amplifi-
cation and nucleotide sequencing of 07V063 (Continued)
Lav92rev caccaatgatgatgataggg 6222-6203
Orf1-11rev cttg caca gaca cagtttt 6720-6702
Orf1-12rev ttcaa ggca gttg tca ggct 7190-7171
Orf1-13rev tca ttaa gacg acacc ggaa 7406-7386
Orf1-14rev cttg ccat cgga cacaa gg 7903-7885
Orf1-15rev tga cacc actg agcg ccga 8396-8378
Orf1-16rev agaca cact ggtg acggggt 8696-8676
Lav51rev aagaaagctgggtttgtcag 8971-8952
Orf1-17rev cggaa tctg tttcaa cacag 9460-9441
Orf1-18rev ccagg tggtt gcaa tatcca 9944-9925
Orf1-19rev aaaactccc gaag ttggtcg 10385-10366
Orf1-20rev aggc ttgc tgtag tgggcat 10762-10743
Lav82rev ttcaagctggaagtaggc 11244-11225
Orf1-21rev tgatttt gctcc acag tgac 11741-11722
Orf2arev tcatr ccc tatt y tgc acca 12558-12539
Orf3rev agaa aa gg cacgc ag aaa gca 13184-13165
Orf4rev cattcagctcgcataicgtcaag 13569-13547
Orf5Pesrev ggg cgt ata tca tta tag gtg 14100-14079
Orf6rev acccagc aa ctgg cacag 14606-14589
Orf7rev tcg ccc taa ttg aa tagg tga 14966-14946
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(81% identity/85% similarity). A major difference is a
deletion of 28 aa in a variable region of Nsp2 (at posi-
tions 683-710). Similar deletions in this region are
known e.g. EuroPRRS has a 17 aa deletion (Figure 2A;
[18]). The deletion in NSP2 in 07V63 could be a unique
marker for this strain.
Strain 07V063 showed 87 - 95% aa identity with LV
for the structural ORFs 2 - 7. We compared GP4 and
GP5 proteins from 07V063 and LV since it has been
shown that these proteins are the main target for neu-
tralizing antibodies. Figure 2B shows an alignment of
ORF4 proteins. Notably is the high variation in the
region 50-70. It has been shown that a neutralizing
A. 
01CB1         SQERPQSSGAAVVLCSPDAKEFEEAAPEEVQESGHKAVHSALLAEGPNNEQVQVVAGEQL 
LV            SQERPQSSGAAVVLCSPDAKEFEEAAPEEVQESGHKAVHSALLAEGPNNEQVQVVAGEQL 
EuroPRRS      SQKRPQSSGAAVALCSSDAEGFEEAAPEGVQERGHKAVHSALFAKGPNNEQVQVVAGEQQ 
SD01-08       FQERPQSPGAAVALCSPDAKGFEGTASEEAQESGHKAVHAVPLAEGPNNEQVQVVAGEQL 
SHE           FQERPQSSGAAVVLCSPDIKEFEEAAPEEVQEGGHKAVHSALLAEGLNNEQVQVVAGAQL 
Amervac       FQERPQSSGAAVVLCSPDIKEFEEAAPEEVQEGGHKAVHSALLAEGLNNEQVQVVAGAQL 
BJEU06-1      SKKNLQRSGAAVVSCSPDAKGSGESALEEIRESDLKAVHSALLAEDPNNEQVRAVAGEKP 
HKEU16        SQDGTQNSGAAVTLHSPDVKEFEGAAPMETQEGNYKADHSALPAGGPDKKQVQAVAGEQL 
KNU-07        PQKKPQSSGTVVVLRSPGAKEFEEAALEEVQESGHKTVHSAPHTKGPNKEQVQVVVGEQL 
07V063        FHERSQGSGTAGVSCSPDAKRFEKATPEEVQEDGHEAVRSTPFTDDP------------- 
NMEU09-1      PQERPQGLSATVVLHSLDAKEFEGTALEEVQKRDHKALHSAVLAEGLSEQQVRTVEGGRS 
               :.  *  .:. .  * . :    ::    :: . :: ::.  : .     . .  *    
 
01CB1         KLGGCGLAVGNAHEGVLVSAGLINLVGGNLSPSDSMKENMLNSRENEPLDLSQPAPAATT 
LV            KLGGCGLAVGNAHEGALVSAGLINLVGGNLSPSDPMKENMLNSREDEPLDLSQPAPASTT 
EuroPRRS      KLGGCGLAIGNAQ-----------------SPLNSMKENMRSSREDEPLDLSQPAPVAAT 
SD01-08       ELGGCGLAIGSAQ-----------------SSSDSKRENMHNSREDEPLDLSHPAPAATT 
SHE           KLGSCGLAVGNTHGGVPVSASPINLADGNLPPSDSMKGNMPNGWEDEPLDLSQSALATTT 
Amervac       KLGSCGLAVGNTHGGVPVSASPINLADGNLPPSDSMKGNMPNGWEDEPLDLSQSALATTT 
BJEU06-1      ELSGCNSAVGVAHEGVLASVG----LGGSLSPSGSMRENIPNSWRDEPLDLSQPTPVATM 
HKEU16        EISGCGSAVGNVHEGVLASSGPINLISGNLPSPGFMKEDTLNSWKDEPLDLSQSAPVTAM 
KNU-07        KLGGCDLVVGNAHEDVLVSAGPIDLAS-------------------EPLDLSRPAPAATT 
07V063        ---------------TLASAGSTNPVDGNLSSSDSAEESTLNSREDEPLDLSQPAPVVTT 
NMEU09-1      ELVGCGLAVRNARDEVP--AGSVNLADGNLPPSDSMEEDMSDNWGNEPLDLSRSALTVTT 
               : .       ..                                 ******:.: . :  
 
B. 
07V063 1    MAAAILFLMVGAQHIMVSEAFACKPCFSTHLSDIKTNTTAAAGFMGLQNIDCLRHHRVTA  60 
            MAAA LF + GAQHIMVSEAFACKPCFSTHLSDI+TNTTAAAGFM LQ+I+C R H V+A 
LV     1    MAAATLFFLAGAQHIMVSEAFACKPCFSTHLSDIETNTTAAAGFMVLQDINCFRPHGVSA  60 
 
07V063 61   AQGRIYTRGPSQCREVVGTPQYITVTANVTDESYLYNADLLMLSACLFYASEMSEKGFKV  120
            AQ +I     SQCRE VGTPQYIT+TANVTDESYLYNADLLMLSACLFYASEMSEKGFKV 
LV     61   AQEKISFGKSSQCREAVGTPQYITITANVTDESYLYNADLLMLSACLFYASEMSEKGFKV  120
 
 
C. 
07V063 1    MRCSHKLGRFLTPHSCFWWLFLLCTGLSWSFADGNGNSSTYQYIYNLTICELNGTTWLSD  60 
            MRCSHKLGRFLTPHSCFWWLFLLCTGLSWSFADGNG+SSTYQYIYNLTICELNGT WLS  
LV     1    MRCSHKLGRFLTPHSCFWWLFLLCTGLSWSFADGNGDSSTYQYIYNLTICELNGTDWLSS  60 
 
07V063 61   HFYWAVETFVLYPVATHILSLGFLTTSHLLDALGLGAVSVAGFHGGRYVLSSVYSACALA  120
            HF WAVETFVLYPVATHILSLGFLTTSH  DALGLGAVS AGF GGRYVL SVY ACA A 
LV     61   HFGWAVETFVLYPVATHILSLGFLTTSHFFDALGLGAVSTAGFVGGRYVLCSVYGACAFA  120
 
07V063 121  ALVCFVIRAAKNCMACRYARTRFTNFIVDDRGRIHRWRSPIVVERLGKADVSGDLVTIKH  180
            A VCFVIRAAKNCMACRYARTRFTNFIVDDRGR+HRW+SPIVVE+LGKA+V G+LVTIKH 
LV     121  AFVCFVIRAAKNCMACRYARTRFTNFIVDDRGRVHRWKSPIVVEKLGKAEVDGNLVTIKH  180
 
07V063 181  VVLEGVKAQPLTRTSAEQWE  200 
            VVLEGVKAQPLTRTSAEQWE 
LV     181  VVLEGVKAQPLTRTSAEQWE  200 
Figure 2 Alignment of Nsp2, ORF4 and ORF5 proteins from 07V063 with LV (ORF4 and ORF5) and a selection of genotype 1 strains
(Nsp2). A. Alignment of Nsp2 proteins from genotype 1 strains. Only aa positions 636-755 (LV) are shown. The deletion in 07V063 is located at
aa positions 683-710. B. Alignment of GP4 from 07V063 and LV (only the first 120 aa are shown). A neutralizing epitope in LV (57-68) is
underlined. C. Alignment of GP5 from 07V063 and LV. A neutralizing epitope in North American strains (37-45) is underlined.
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this region is under antibody-mediated pressure in vitro
and in vivo [20,21]. Pigs infected with 07V063 produce
neutralizing antibodies against the
57RVTAAQGRIYTR
68
epitope. However, these antibodies do not cross-protect
against LV [22]. Similarly, antibodies against the same
region in LV, do not cross-protect against 07V063.
Interestingly, this lack of cross-neutralization is in agree-
ment with the finding that strain 07V063 was able to
replicate and cause disease on a farm where animals
were vaccinated with the LV-like Porcilis™ vaccine.
GP5 has been described as the main target for virus-
neutralizing antibodies in North American PRRSV
strains. A neutralizing epitope has been identified at
positions 37-45 [23]. Figure 2C shows that 07V063 and
LV have an identical sequence from 37-45 with the
exception of an extra glycosylation site at position 37 in
07V063. It has been shown that several strains are gly-
cosylated at this position but the significance of this gly-
cosylation is not known. Other amino acid changes
occur throughout the sequence and several of these
positions have been described as variable [24]. No other
differences in glycosylation pattern of the structural pro-
teins between 07V063 and LV was observed.
Phylogenetic relationship of 07V063
Since ORF5 is frequently used as a marker for the study
of genetic relationships [8], we constructed phylogenetic
trees using ORF5 sequences from a selection of geno-
type 1 strains (Table 4). In addition genotype 1 strains
for which the full length sequence was available in Gen-
bank were included. VR-2332 (genotype 2) was used as
out-group.
Figure 3A shows a phylogenetic tree of ORF5 DNA
sequences based on the Neighbour Joining (NJ) method.
Several clusters are evident and supported by high boot-
strap values. It can be concluded that 07V063 clusters
within the pan-European subtype 1 [8]. Within subtype
1, a cluster with LV- and Olot/91-like strains can be dis-
tinguished. Although both LV and Olot/91 belong to the
earliest PRRSV isolates, still LV and Olot/91-like strains
such as SD01-08 are circulating. Strain 07V063 is
genetically different from LV- and Olot/91- like strains.
Apparently 07V063 clusters together with isolates from
different geographical locations e.g. isolates from Spain
(16/2000), Denmark (361-4), China (BJEU06-1) and
South-Korea (IV3140) although this clustering is not
supported by high bootstrap values. A similar tree topol-
ogy was obtained using ORF5 protein sequences (data
not shown). The sub-clustering of type 1 is complex and
cannot always be explained by geographic isolation of
the strains [8]. The sequence of 07V63 adds to the
increase of genetic diversity of type 1 strains and is an
example of continuous genetic drift within PRRSV [24].
A recent PRRSV study in Spain [25] demonstrated that
Spanish isolates from different years show continuous
evolution and increase in heterogeneity and that differ-
ent genotypes and variants within the genotypes co-
circulate.
Table 4 Overview of strains used for phylogenetic
analysis
Strain Genotype Genbank
Accession ORF5
Genbank Accession
ORF1a (nsp2)
VR-2332 2 U87392 U87392
Lelystad 1 (subtype 1) M96262 M96262
EuroPRRS 1 AY366525 AY366525
01-CB1 1 (subtype 1) DQ864705 DQ864705
Amervac 1 (subtype 1) GU067771 GU067771
HKEU16 1 (subtype 1) EU076704 EU076704
KNU-07 1 (subtype 1) FJ349261 FJ349261
SHE 1 (subtype 1) GQ461593 GQ461593
SD01-08 1 (subtype 1) DQ489311 DQ489311
BJEU06-1 1 (subtype 1) GU047344 GU047344
NMEU09-
1
1 (subtype 1) GU047345 GU047345
07V063 1 (subtype 1) GU737264 GU737264
PyrsVac 1 (subtype 1) DQ324681 ND
Porcilis 1 (subtype 1) AAW78901 ND
Olot/91 1 (subtype 1) X92942 ND
Yuz-34 1 (subtype 3) DQ324692 ND
Bel-42 1 (subtype 3) DQ324669 ND
Obu-1 1 (subtype 3) DQ324671 ND
Soz-6 1 (subtype 3) DQ324686 ND
Dzi-62 1 (subtype 1) DQ324675 ND
Cresa11 1 (subtype 1) DQ009626 ND
IV3140 1 (subtype 1) DQ355821 ND
28639/98 1 (subtype 1) AY035912 ND
361-4 1 (subtype 1) AY035915 ND
Sno-4 2 (subtype 2) DQ324683 ND
Sid 2 (subtype 2) DQ324682 ND
Aus 2 (subtype 2) DQ324667 ND
Okt-35 1 DQ324677 ND
16/2000 1 DQ345743 ND
SD02-11 1 (subtype 1) AY395078 AY383634
SD01-07 1 (subtype 1) AY395079 AY383632
SD03-12 1 (subtype 1) AY395074 AY383635
SD03-15 1 (subtype 1) AY395076 AY383636
It-22 1 (subtype 1) AY739978 ND
It-39 1 (subtype 1) AY739995 ND
It-44 1 (subtype 1) AY740000 ND
It-35 1 (subtype 1) AY739991 ND
It-13 1 (subtype 1) AY739969 ND
Lena 1 (subtype 3) EU909691 ND
The type of the strains is according to Stadejek et al (2008). ND = no data. VR-
2332 is genotype 2. Eleven genotype 1 isolates for which full length
sequences were obtained are listed first.
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(Figure 3B). Sequences from all known full length geno-
type 1 strains (Table 4) were included. Essentially, the
same topology can be observed as for ORF5. A cluster
of LV-like strains is evident and supported by high
bootstrap values. As was already observed from the
ORF5 phylogenetic tree, Amervac and SHE are very clo-
s e l yr e l a t e da si st h ec a s ef o rs t r a i n s0 1 - C B 1a n dL V .
07V063 clusters apart from LV and is genetically dis-
tinct from the LV prototype.
Conclusions
By using a simple random PCR cloning approach we
obtained PRRSV sequence data from a recent European
PRRSV isolate of unknown genetic background. This
approach can be used to obtain partial genome
sequences from for instance East-European type strains
(for which until present, no full length genomes are
available) and to get a better knowledge of the increas-
ing PRRSV variability. We also showed that the isolate
sequenced in this study is genetically different from pro-
totype LV.
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transcriptase polymerase chain reaction.
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